Physician profile
Amit Bhargava
NPI 1699749440
$2,189.08
in general payments reported to CMS, 2019-2025
24 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $51.31 · 2021: $77.79 · 2022: $594 · 2023: $368 · 2024: $268 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.34 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $455.20 | 2022 | |
| Baxter Healthcare | $264.10 | 2021-2024 | Renal - Pd |
| Otsuka America Pharmaceutical, INC. | $224.43 | 2019-2025 | Jynarque, Voyxact |
| Vantive US Healthcare LLC | $168.88 | 2025 | Renal - Pd |
| Amgen INC. | $165.67 | 2021-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $139.24 | 2019-2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $99.94 | 2019 | |
| Osprey Medical INC | $99.00 | 2019 | |
| Novo Nordisk INC | $62.23 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $59.42 | 2019-2025 | Farxiga |
| Fresenius USA Marketing, INC. | $59.02 | 2022-2023 | Velphoro, Korsuva |
| Ardelyx, INC. | $57.97 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $52.34 | 2023-2025 | |
| Glaxosmithkline, LLC. | $41.08 | 2022-2025 | Benlysta |
| Vifor Pharma, INC. | $40.55 | 2020-2024 | Veltassa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $27.75 | 2024 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.46 | 2025 | Jardiance |
| Abbott Laboratories | $25.43 | 2022 | |
| Mallinckrodt Hospital Products INC. | $23.09 | 2024 | Terlivaz |
| Opko Pharmaceuticals, LLC | $21.49 | 2023 | Rayaldee |
| Genzyme Corporation | $20.41 | 2019 | |
| Scpharmaceuticals INC. | $20.11 | 2025 | |
| Renalytix Ai, INC. | $19.96 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Aurinia Pharma U.S., INC. | $14.31 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Bhargava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.